NASDAQ$ASTH

Astrana Health Inc · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

Announced second quarter 2021 results, showing revenue increase and raised full-year guidance.

Apollo Medical Holdings reported a 6% increase in revenue to $175.6 million and an 80% increase in net income attributable to ApolloMed to $12.7 million for the second quarter of 2021. The company also raised its full-year 2021 guidance due to continued organic growth and encouraging results in the first half of the year.

  • Q2 earnings per share - diluted (“EPS - diluted”) of $0.28 per share, up 47% from the prior-year quarter
  • Q2 total revenue of $175.6 million, up 6% from the prior-year quarter
  • Q2 net income attributable to ApolloMed of $12.7 million, up 80% from the prior-year quarter
  • ApolloMed completed the successful refinancing of its existing term loan and revolving credit facility with a new five-year revolving credit facility of $400.0 million

Headline financials

Total Revenue

$176M

Previous: $165M+6.3%
EPS (adj)

$0.23

Previous: $0.20+15.0%
Adjusted EBITDA

$30.7M

Previous: $23.6M+30.2%
Capital Expenditures

-$7.36M

Previous: -$451K-1532.8%
Free Cash Flow

$5.29M

Previous: $6.59M-19.7%
Net Income

$12.7M

Previous: $7.04M+79.7%
Operating Income

$21M

Previous: $12.9M+62.6%
Gross Profit

-$140M

Previous: $29.1M-581.9%
Cash & Equivalents

$177M

Previous: $152M+16.3%
Total Assets

$894M

Previous: $833M+7.3%
Stock-Based Comp

$1.56M

Previous: $852K+82.6%

Revenue & EPS history

Astrana Health · Revenue · Quarterly

$176M

Q2 2021+6.3%vs Q2 2020
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Forward guidance

ApolloMed is raising its full-year 2021 guidance as a result of continued organic growth and encouraging results in the first half of the year.

Tailwinds

  • Total revenue is expected to be between $700 million and $720 million.
  • Net income is expected to be between $56 million and $66 million.
  • Net income attributable to ApolloMed is expected to be between $48 million and $58 million.
  • EBITDA is expected to be between $100 million and $119 million.
  • Adjusted EBITDA is expected to be between $120.5 million and $130.5 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

+0.7%

Avg return

Earnings day

-2.1%

Avg return

5 days after

+2.1%

Avg return

30 days after

40%

23 / 57 earnings

Positive

+83.3%

Q3 2011

Best reaction

-40.5%

Q2 2012

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+29.4%+22.5%+20.6%
Q3 2025-23.4%-29.4%-33.8%
Q1 2025-11.1%-20.8%-24.5%
Q4 2024-26.8%+5.0%+16.1%
Q3 2024-21.1%-27.9%-30.4%
Q2 2024-1.4%-1.8%+0.1%
Q1 2024-0.7%+1.5%+8.0%
Q4 2023+2.3%+1.8%-1.9%
Q3 2023+9.3%+2.9%+13.4%
Q2 2023+4.2%+3.5%-17.4%
Q1 2023+5.4%+7.0%-0.8%
Q4 2022+6.9%+5.2%+15.2%
Q3 2022+8.4%+8.9%-14.5%
Q2 2022-4.3%-11.0%-29.3%
Q1 2022-0.5%-5.4%-26.4%
Q4 2021-2.0%-11.0%-7.0%
Q3 2021+14.7%+30.5%+0.8%
Q2 2021-11.8%-10.7%-12.9%
Q1 2021+4.5%+4.7%+10.9%
Q4 2020+9.1%+8.8%+8.3%
Q3 2020-1.2%-1.6%+0.5%
Q2 2020+1.8%+2.4%+7.9%
Q1 2020-10.4%-11.6%+13.1%
Q4 2019-12.9%-24.0%+7.0%
Q3 2019-2.9%-0.9%+25.0%
Q2 2019-5.0%+4.8%+31.1%
Q1 2019-1.2%-4.3%-29.7%
Q4 2018-6.4%-8.3%-6.9%
Q3 2018+26.3%+4.0%-4.6%
Q2 2018-13.7%-23.3%-32.2%
Q4 2017+10.8%-6.3%+2.1%
Q1 2018+10.8%-6.3%+2.1%
Q3 2017+3.9%+3.9%+140.0%
Q2 2017+0.0%+0.0%-10.5%
Q1 2017+0.0%+6.7%+36.7%
Q1 2016+4.0%+4.0%+0.0%
Q3 2016-4.8%
Q2 2016-12.9%
Q1 2015-6.5%
Q3 2015-3.2%
Q2 2015+0.0%
Q2 2014+15.6%
Q4 2013
Q3 2013+1.6%
Q2 2013+13.5%
Q1 2013-13.3%
Q4 2012-2.2%
Q3 2012-9.1%
Q2 2012-40.5%
Q1 2012+0.0%
Q4 2011
Q3 2011+83.3%
Q2 2011+0.5%
Q1 2011-0.5%
Q4 2010-3.9%
Q3 2010+19.0%
Q2 2010+0.0%
Q1 2010-2.1%
Q4 2009+9.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro